Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11611151 | 0.86 | CYP3A4 (0.42) | POLBHTTMAPTKDM4EGAA | |
| SCHEMBL11611146 | 0.84 | CYP3A4 (0.44) | POLBHTTMAPTKDM4EGAA | |
| SCHEMBL27298985 | 0.83 | POLB (0.44) | POLBHTTACHEMAPTKDM4E | |
| SCHEMBL15388582 | 0.83 | POLB (0.41) | POLBHTTACHEMAPTKDM4E | |
| SCHEMBL2910532 | 0.82 | POLB (0.62) | POLBHTTACHEMAPTKDM4E | |
| SCHEMBL2114307 | 0.81 | POLB (0.53) | POLBHTTACHEMAPTKDM4E | |
| SCHEMBL28294695 | 0.81 | CYP3A4 (0.42) | POLBHTTMAPTKDM4EGAA | |
| SCHEMBL4472816 | 0.81 | POLB (0.45) | POLBHTTACHEMAPTKDM4E | |
| SCHEMBL15642113 | 0.80 | POLB (0.65) | POLBHTTACHEMAPTKDM4E | |
| SCHEMBL5958117 | 0.79 | ELANE (0.42) | POLBMAPTHPGDCYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018108606-A1 | PROCESS FOR THE MANUFACTURE OF 6,10-DIMETHYLUNDECAN-2-ONE, ISOPHYTOL, ALPHA-TOCOPHEROL (ACETATE) AND FURTHER INTERMEDIATES THEREOF | DSM IP ASSETS B.V. (NL) | 2018-06-21 | — | — | WO | claimed |
| EP-1239045-B1 | Process for the manufacture of a vitamin E intermediate | DSM IP ASSETS BV (NL) | 2010-08-25 | — | — | EP | claimed |
| EP-1562929-B1 | MANUFACTURE OF TOCOPHERYL ACETATE | DSM IP ASSETS BV (NL) | 2007-11-14 | — | — | EP | claimed |
| US-6790967-B2 | PREPARING ALPHA-TOCOPHEROL BY THE CONDENSATION OF A PHYTOL WITH TRIMETHYLHYDROQUINONE IN A POLAR ESTER SOLVENT AND IN THE PRESENCE OF A BRONSTED ACID, A ZINC HALIDE AND WATER, THE WATER PREVENTING SIDE REACTIONS OF TMHQ AT THE BEGINNING | ADISSEO FRANCE S.A.S. (FR) | 2004-09-14 | — | — | US | claimed |
| US-6743615-B2 | CONVERTING TRIMETHYLHYDROQUINONE DIACETATE (TMHQ-DA) INTO THE CORRESPONDING MONOACETATE (TMHQ-1-MA) WITH A LIPASE | ROCHE VITAMINS, INC. | 2004-06-01 | — | — | US | claimed |
| EP-1114041-B1 | PROCESS FOR THE PREPARATION OF ALPHA-TOCOPHEROL ACETATE | AVENTIS ANIMAL NUTRITION SA (FR) | 2004-03-31 | — | — | EP | claimed |
| US-20020161246-A1 | Process for the manufacture of a vitamin E intermediate | DSM NUTRITIONAL PRODUCTS, INC. | 2002-10-31 | — | — | US | claimed |
| EP-1239045-A1 | Process for the manufacture of a vitamin E intermediate | Roche Vitamins AG (CH) | 2002-09-11 | — | — | EP | claimed |
| US-6441249-B2 | ACID CATALYSIS OF ISOPHERONE, DISTILLATION, OXIDATION IN AMORPHOUS CARBON AND BASE FORMING 4-OXOISOPHORONE WHICH REACTS WITH ACID ANHYDRIDE/CARBOXYLIC ACID TO FORM COMPOUND HYDROLYZED TO TRIMETHYLHYDROQUINONE; EFFICIENCY; VITAMIN E | NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) | 2002-08-27 | — | — | US | claimed |
| US-6320086-B1 | REACTING ISOPHORONE OVER ACID CATALYST, DISTILLING FORMED BETA-ISOPHORONE, OXIDIZING IN PRESENCE OF AMORPHOUS CARBON AND BASE TO 4-OXOISOPHORONE, REACTING IN VAPOR PHASE WITH CARBOXYLIC ACID USING SOLID ACID CATALYST, HYDROLYZING ESTER | NIPPON PETROCHEMICALS COMPANY LIMITED (JP) | 2001-11-20 | — | — | US | claimed |
| US-20010039366-A1 | Method for producing trimethylhydroquinone | NIPPON PETROCHEMICALS COMPANY LIMITED | 2001-11-08 | — | — | US | claimed |
| US-6211418-B1 | DISTILLING ISOPHORONE WITH ACID CATALYST TO RECOVER BETA-ISOPHORONE, OXIDIZING IN PRESENCE OF AMORPHOUS CARBON AND BASE TO 4-OXOISOPHORONE, REACTING IN VAPOR PHASE WITH CARBOXYLIC ACID USING SOLID ACID CATALYST, HYDROLYZING | NIPPON PETROCHEMICALS COMPANY LIMITED (JP) | 2001-04-03 | — | — | US | claimed |
| JP-11255707-A | — | — | None | — | — | JP | disclosed |
| JP-11049711-A | — | — | None | — | — | JP | disclosed |
| JP-11049710-A | — | — | None | — | — | JP | disclosed |
| WO-2018108606-A1 | PROCESS FOR THE MANUFACTURE OF 6,10-DIMETHYLUNDECAN-2-ONE, ISOPHYTOL, ALPHA-TOCOPHEROL (ACETATE) AND FURTHER INTERMEDIATES THEREOF | DSM IP ASSETS B.V. (NL) | 2018-06-21 | — | — | WO | disclosed |
| JP-H11255707-A | PRODUCTION OF TRIMETHYLHYDROQUINONES | NIPPON PETROCHEM CO LTD | 1999-09-21 | — | — | JP | disclosed |
| EP-0924208-A1 | Process for the preparation fo alpha-Tocopherol esters | Degussa Aktiengesellschaft (DE) | 1999-06-23 | — | — | EP | disclosed |
| JP-H1149710-A | PRODUCTION OF TRIMETHYLHYDROQUINONES | NIPPON PETROCHEM CO LTD | 1999-02-23 | — | — | JP | disclosed |
| JP-H1149711-A | PRODUCTION OF TRIMETHYLHYDROQUINONE | NIPPON PETROCHEM CO LTD | 1999-02-23 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039366-A1 | Method for producing trimethylhydroquinone | APEH, CYP46A1, MSMO1 | POLB 1081/4885HTT 2203/4885ACHE 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.